Lucid Diagnostics Inc LUCD

NAS: LUCD | ISIN: US54948X1090   17/05/2024
0,905 USD (+1,69%)
(+1,69%)   17/05/2024

14 mei 2024 · PAVmed Provides Business Update and First Quarter 2024 Financial Results · Persbericht

13 mei 2024 · Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results · Persbericht

9 mei 2024 · Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall · Persbericht

7 mei 2024 · Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors · Persbericht

2 mei 2024 · Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 · Persbericht

2 mei 2024 · Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing · Persbericht

29 april 2024 · Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month · Persbericht

8 april 2024 · Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

27 maart 2024 · PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results · Persbericht

25 maart 2024 · Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results · Persbericht

21 maart 2024 · Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population · Persbericht

20 maart 2024 · Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference · Persbericht

12 maart 2024 · Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 · Persbericht

16 februari 2024 · Lucid Diagnostics Provides Update Regarding World Trade Center Health Program · Persbericht

15 februari 2024 · Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony · Persbericht

8 februari 2024 · Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors · Persbericht

12 december 2023 · Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies · Persbericht

11 december 2023 · PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders · Persbericht

4 december 2023 · PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split · Persbericht

9 november 2023 · Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day · Persbericht

Mijn selecties